Products for Research Use Only
RegisterLogin

JNU-0921

CAT: 0804-HY-161982-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-161982-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
JNU-0921 is a potent and orally active CD137 agonist. JNU-0921 increases the mRNA expression of IFN-γ and GZMB. JNU-0921 induces luciferase activity with an EC50 value of 64.07 nM.JNU-0921 enhances effector and memory function of cytotoxic CD8+ T cells (CTLs) and alleviates their exhaustion. JNU-0921 also skews polarization of helper T cells toward T helper 1 type and enhances their activity to boost CTL function. JNU-0921 shows anticancer activity[1].
UNSPSC
12352005
Target
TNF Receptor
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jnu-0921.html
Purity
99.77
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(O)C1=CC(C2=NOC(C3=CC(C=CC=C4)=C4C=C3)=N2)=CC=C1
Molecular Formula
C19H12N2O3
Molecular Weight
316.31
References & Citations
[1]Liu L, et al. Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8+ T cells in cis and in trans. Sci Adv. 2024 Aug 23;10 (34) :eadp8647.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-174421FAPI-JNU
HY-19394CLX-0921
HY-19394A-01(E) -CLX-0921
HY-111484-01GDC-0927
HY-145384-01ROC-0929
HY-173459N-0920
HY-120207-01(R) -GDC-0927
HY-111484AGDC-0927 (Racemate)
HY-173615KTD-092

Alternative Products

CatalogName
T89884-01JNU-0921
T211034-01FAPI-JNU
BUP00950-01THR-0921
GTR19197871-01CLX 0921

Popular Products